Anda di sini
Formulari Ubat KKM (FUKKM)
| # | Generic Name | MDC | Category | Indications | Pres. Restrictions | Dosage |
|---|---|---|---|---|---|---|
| 1621 | Trimetazidine 20 mg Tablet | C01EB15110T1001XX | B | Prophylactic treatment of episodes of angina pectoris | 20 mg 3 times daily | |
| 1622 | Trimetazidine 35mg MR Tablet | C01EB15110T5001XX | B | Prophylactic treatment of episodes of angina pectoris | 35 mg twice daily in the morning and evening with meals | |
| 1623 | Trimethoprim 100mg Tablet | J01EA01-000-T10-01-XXX | B | Treatment of urinary tract infections due to susceptible pathogens | None | ADULT: 200 mg daily in 1 or 2 divided doses or 300 mg daily as a single dose. Acute infection: 200 mg twice daily. CHILD: 6-8 mg/kg/day in 2 divided doses. 6 - 12 years: 100 mg twice daily; 6 months - 5 years: 50 mg twice daily. 6 weeks - 5 months: 25mg twice daily |
| 1624 | Trimethoprim 300mg Tablet | J01EA01-000-T10-02-XXX | B | Treatment of urinary tract infections due to susceptible pathogens | None | ADULT: 200 mg daily in 1 or 2 divided doses or 300 mg daily as a single dose. Acute infection: 200 mg twice daily. CHILD: 6 - 12 years: 100 mg twice daily; 6 months - 5 years: 50 mg twice daily. 6 weeks - 5 months: 25mg twice daily |
| 1625 | Trioxsalen 5 mg Tablet | D05BA01000T1001XX | A | Vitiligo | 5 - 10 mg daily, 2 - 4 hours before exposure to sunlight. To increase pigmentation: 10 mg daily, 2 hours prior to UV irradiation | |
| 1626 | Triprolidine HCl 1.25mg and Pseudoephedrine HCl 30mg/5ml Syrup | R01BA52-110-L90-01-XXX | B | Decongestion of the upper respiratory tract in common cold, hay fever, allergic and vasomotor rhinitis and sinusitis. Doses to be taken twice daily or three times daily | None | Adult and children over 12 years: 10ml 3 times a day (max 4 times a day). CHILD: 6 - 12 years: 5 ml (6-8 hourly). 2 - 5 years: 2.5 ml (6-8 hourly). |
| 1627 | Triprolidine HCl 2.5mg and Pseudoephedrine HCl 60mg Tablet | R01BA52-988-T10-02-XXX | B | Decongestion of the upper respiratory tract in common cold, hay fever, allergic and vasomotor rhinitis and aerotitis | None | ADULT 2.5 mg every 4 - 6 hours; maximum dose 10 mg/day. CHILD (syrup) 6 - 12 years : 1.25 mg every 4 - 6 hours; maximum dose 5 mg/day 4 - 6 years : 0.938 mg every 4 - 6 hours; maximum dose 3.744 mg/day 2 - 4 years : 0.625 mg every 4 - 6 hours; maximum dose 2.5 mg/day |
| 1628 | Triptorelin 3.75 mg Injection | L02AE04000P2001XX | A | i) Treatment of confirmed central precocious puberty (preterm sexual development) (before 8 years in girls and 10 years in boys) ii) Genital and extragenital endometriosis (stage I to stage IV). Treatment should not be administered for more than 6 months. It is not recommended to start a second treatment course with triptorelin or another GnRH analogue. | 1 intramuscular injection every 4 weeks. The treatment must be started in the first 5 days of the menstrual cycle. The duration of treatment depends on the initial severity of the endometriosis and the changes observed in the clinical features. In principle, the treatment should be administered for at least 4 months and for at most 6 months. It is not recommended to start a second treatment course with triptorelin or another GnRH analogue. | |
| 1629 | Triptoreline 11.25mg Powder and Solvent for Suspension for Injection | L02AE04-127-P40-01-xxx | A | i. Treatment of confirmed central precocious puberty (preterm sexual development) (before 8 years in girls and 10 years in boys) ii. Genital and extragenital endometriosis (stage I to stage IV). Treatment should not be administered for more than 6 months. It is not recommended to start a second treatment course with triptorelin or another GnRH analogue. iii. Treatment of locally advanced prostate cancer when used alone or as concomitant and adjuvant radiotherapy. iv. Treatment of metastatic prostate cancer. | Indikasi i: First-line treatment for central precocious puberty Indikasi ii: Second-line treatment for genital and extragenital endometriosis | indikasi i: Children over 20 kg in body weight: One intramuscular injection of triptorelin 11.25 mg administered every 3 months. Treatment should be stopped around the physiological age of puberty in boys and girls and it is recommended that treatment is not continued in girls with a bone maturation of more than 12 to 13 years. There are limited data available in boys relating to the optimum time to stop treatment based on bone age, however it is advised that treatment is stopped in boys with a bone maturation age of 13 to 14 years. Indikasi ii: One intramuscular injection of triptorelin repeated every 3 months. The subcutaneous administration has not been studied in women. The treatment must be started in the first five days of the menstrual cycle. Duration of treatment: This depends on the initial severity of the endometriosis and the changes observed in the clinical features (functional and anatomical) during treatment. The treatment should not be administered for more than 6 months Indikasi iii & iv: 11.25mg every 3 months |
| 1630 | Tropicamide 1% Eye Drops | S01FA06-000-D20-02-XXX | A/KK | Topical use to produce cycloplegic refraction for diagnostic purposes | None | 1 - 2 drops several times a day |
| 1631 | Trospium Chloride 20mg coated tablet | G04BD09-100-C10-01-XXX | A* | Symptomatic treatment for urge incontinence and/or increased urinary frequency and urgency as may occur in patients with overactive bladder (eg. Idiopathic or neurologic detrusor overactivity) | Place in therapy: As first line treatment for overactive bladder in patients with Parkinsonism, Alzheimer's or other cognitive disease | 1 tablet twice daily. Tablet should be swallowed whole with a glass of water before meals on empty stomach. Severe renal impairment (CrCl between 10 & 30 mL/min/1.73 m2): 1 tab daily or every other day |
| 1632 | Tuberculin PPD Injection | V04CF01000P3001XX | B | For routine Mantoux (tuberculin sensitivity) test | 10 units is injected intradermally | |
| 1633 | Typhoid Vaccine Capsule | J07AP01000C1001XX | B | Active immunization against typhoid fever in adult and child 6 years of age or older | ADULT and CHILD 6 years of age or older, 1 capsule on days 1, 3 and 5 | |
| 1634 | Typhoid Vaccine Injection | J07AP02000P3001XX | B | Active immunization against typhoid fever in adult and child more than 2 years | 0.5 ml single IM injection into the deltoid or vastus lateralis, may reimmunize with 0.5 ml IM every 3 years if needed. | |
| 1635 | Ulipristal Acetate 30mg Tablet | G03AD02-122-T10-01-XXX | A | Emergency contraception within 120 hours (5 days) of unprotected sexual intercourse for sexual assault victim. | - | 30mg orally as soon as possible, but no later than 120 hours (5 days) after unprotected sexual intercourse or contraceptive failure. |
| 1636 | Umeclidinium 62.5mcg and Vilanterol 25mcg inhalation | R03AL03-989-A20-01-XXX | A* | Indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD). | None | One inhalation daily |
| 1637 | Upadacitinib 15mg Extended-Release Film Coated Tablet | L04AA44-020-T50-01-XXX | A* | 1. Indicated for the treatment of severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. 2. Indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more DMARDs. May be used as monotherapy or in combination with methotrexate. 3. Indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). Upadacitinib may be used as monotherapy or in combination with methotrexate. 4. For the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent. 5. For the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent. | Indication 1 (severe atopic dermatitis): i. As fourth line of treatment in patients who have failed / have contraindications / experienced adverse events to: • Intensive and optimized topical treatment • Phototherapy • At least two immunosuppressants ii. To be prescribed by Dermatologists only. Indication 2 (active psoriatic arthritis): To be prescribed by Rheumatologist only Indication 3 (moderate to severe active rheumatoid arthritis): i. To be prescribed after failing/ intolerance/ contraindicated to csDMARDs (as per Malaysian Consensus on Biologic Usage) and one biologic DMARDs. ii. To be prescribed by Rheumatologist only Indication 4 (active ulcerative colitis): As a second line therapy and to be prescribed by gastroenterologists experienced in inflammatory bowel disease management. Indication 5 (Crohn's disease) - None | Indication 1 (severe atopic dermatitis): Adults: The recommended dose of upadacitinib is 15 mg or 30 mg once daily based on individual patient presentation (Refer to package insert). The lowest effective dose for maintenance should be considered. Adolescents (from 12 to 17 years of age): The recommended dose of upadacitinib is 15 mg once daily for adolescents weighing at least 40 kg. Upadacitinib can be used with or without concomitant topical therapies (Refer package insert) Indication 2 & 3 (active psoriatic arthritis & moderate to severe active rheumatoid arthritis): 15 mg once daily Indication 4 (active ulcerative colitis): Induction The recommended induction dose of upadacitinib is 45 mg once daily for 8 weeks. Maintenance The recommended maintenance dose of upadacitinib is 15 mg or 30 mg once daily based on individual patient presentation. Indication 5 (Crohn's disease) Induction The recommended induction dose of upadacitinib is 45 mg once daily for 12 weeks. Maintenance The recommended maintenance dose of upadacitinib is 15 mg or 30 mg once daily based on individual patient presentation. |
| 1638 | Upadacitinib 30mg Extended-Release Film Coated Tablet | L04AA44-020-T50-02-xxx | A* | 1. For the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent. 2. For the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent. | Indication 1 (active ulcerative colitis) As a second line therapy and to be prescribed by gastroenterologists experienced in inflammatory bowel disease management. Indication 2 (Crohn's disease) - None | Indication 1 (active ulcerative colitis) Induction The recommended induction dose of upadacitinib is 45 mg once daily for 8 weeks. Maintenance The recommended maintenance dose of upadacitinib is 15 mg or 30 mg once daily based on individual patient presentation. Indication 2 (Crohn's disease) Induction The recommended induction dose of upadacitinib is 45 mg once daily for 12 weeks. Maintenance The recommended maintenance dose of upadacitinib is 15 mg or 30 mg once daily based on individual patient presentation. |
| 1639 | Upadacitinib 45mg Extended-Release Film Coated Tablet | L04AF03-020-T50-01-xxx | A* | 1. For the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent. 2. For the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent. | Indication 1 (active ulcerative colitis) As a second line therapy and to be prescribed by gastroenterologists experienced in inflammatory bowel disease management. Indication 2 (Crohn's disease) - None | Indication 1 (active ulcerative colitis) Induction The recommended induction dose of upadacitinib is 45 mg once daily for 8 weeks. Maintenance The recommended maintenance dose of upadacitinib is 15 mg or 30 mg once daily based on individual patient presentation. Indication 2 (Crohn's disease) Induction The recommended induction dose of upadacitinib is 45 mg once daily for 12 weeks. Maintenance The recommended maintenance dose of upadacitinib is 15 mg or 30 mg once daily based on individual patient presentation. |
| 1640 | Urofollitropin (FSH) 150 IU Injection | G03GA04-000-P30-02-XXX | A* | For stimulation of follicular growth in the treatment of infertility | To be individualised. Initial: 75 IU-150 IU daily for 7 days and then may be increased or decreased by 75 IU/day according to follicular response. Max : 450 IU/day. In-vitro fertilisation: Initial: 150 IU daily from Cycle Day 2 or Day 3 until sufficient follicular development is attained. | |
| 1641 | Urofollitropin (FSH) 75 IU Injection | G03GA04-000-P30-01-XXX | A* | For stimulation of follicular growth in the treatment of infertility | - | To be individualised. Initial: 75 IU-150 IU daily for 7 days and then may be increased or decreased by 75 IU/day according to follicular response. Max : 450 IU/day. In-vitro fertilisation: Initial: 150 IU daily from Cycle Day 2 or Day 3 until sufficient follicular development is attained |
| 1642 | Urokinase 250,000 IU Injection | B01AD04-000-P40-04-XXX | A | Treatment of thromboembolic disease such as mycocardial infarction, peripheral artery occlusion, pulmonary embolism, retinal artery thrombosis and other ophthalmologic use | ADULT: Acute pulmonary embolism: IV loading dose 4400 iu/kg over 10 mins, maintenance 4400 iu/kg/hour for 12 hours. Peripheral vascular occlusion: infuse 2500 iu/ml into clot at a rate of 4000 iu/min for 2 hours. This may be repeated up to 4 times. Hyphaema: 5000 IU in 2 ml saline solution is injected and withdrawn repeatedly over the iris. If residual clot remains, leave 0.3ml in the anterior chambers for 24-48 hours to facilitate futher dissolution | |
| 1643 | Ursodeoxycholic Acid 250 mg Capsule | A05AA02-000-C10-01-XXX | A | Cholestatic liver diseases (eg. primary biliary cholangitis, primary cholangitis etc.) | - | 10-15 mg/kg daily in 2 to 3 divided doses Dosing is individualised based on body weight and according to product insert/protocol |
| 1644 | Ustekinumab 90 mg/ml Injection | L04AC05000P3002XX | A* | Treatment of moderate to severe plaque psoriasis in adults who failed to, or who have contraindication to, or are intolerant to conventional systemic therapies including ciclosporin, methotrexate and photochemotherapy (PUVA). | Body weight less than 100kg: Initial dose of 45 mg SC, followed by 45 mg 4 weeks later, then every 12 weeks thereafter. Body weight more than 100 kg: initial dose 90 mg SC, followed by 90 mg 4 weeks later, & then every 12 weeks thereafter. | |
| 1645 | Valganciclovir 450mg Tablet | J05AB14-110-T10-01-XXX | A* | For the prevention of cytomegalovirus (CMV) disease in CMV-negative patients who have received a solid organ transplant from a CMV-positive donor | None | For adult patients who have received other than kidney transplant, the recommended dose is 900 mg (two 450 mg tablets) once a day starting within 10 days of transplantation until 100 days post-transplantation. For adult patients who have received a kidney transplant, the recommended dose is 900 mg (two 450 mg tablets) once a day starting within 10 days of transplantation until 200 days post-transplantation. |
| 1646 | Valproic Acid and Sodium Valproate (ER) 500mg Tablet | N03AG01-520-T50-01-XX | B | i) In the treatment of generalized or partial epilepsy, particularly with the following patterns of seizures:absence, myoclonic, tonic-clonic, atonic-mixed as well as, for partial epilepsy:simple or complex seizures, secondary generalized seizures, specific syndrome (West, Lennox-Gastatut). ii) Treatment and prevention of mania associated with bipolar disorders. | None | i) Adults: Dosage should start at 500mg daily increasing by 200mg at three-day intervals until control is achieved. This is generally within the dosage range 1000mg to 2000mg per day. Children: >20KG: 500mg/day (irrespective of weight) with spaced increases until control is achieved. ii) Initial dose of 1000mg/day, to be increase rapidly as possible to achieve lowest therapeutic dose, which produce desired clinical effects. Recommend initial dose is 1000mg & 2000mg daily. Max dose 3000mg daily. |
| 1647 | Valsartan 160 mg and Hydrochlorothiazide 12.5 mg Tablet | C09DA03935T1005XX | A/KK | Hypertension in patients intolerant to ACE inhibitors | Initial: Valsartan/Hydrochlorothiazide 80/12.5mg once daily Max: Valsartan/Hydrochlorothiazide 320/25mg once daily Dosing is individualised and according to product insert / protocol. | |
| 1648 | Valsartan 160 mg Tablet | C09CA03000T1002XX | A/KK | Patients intolerant to ACE inhibitors in: i) Heart failure ii) Post myocardial infarction iii) Hypertension | i) Initial: 40mg twice daily. Titrate up to highest tolerated dose. Max: 320mg daily in divided doses ii) Initial: 20mg twice daily Titrate up to 160mg over next few weeks. Max: 160mg twice daily iii) 80mg or 160mg once daily Max: 320mg daily Dosing is individualised and according to package insert / protocol. | |
| 1649 | Valsartan 80 mg and Hydrochlorothiazide 12.5 mg Tablet | C09DA03-935-T10-01-XXX | A/KK | Hypertension in patients intolerant to ACE inhibitors | Initial: Valsartan/Hydrochlorothiazide 80/12.5mg once daily Max: Valsartan/Hydrochlorothiazide 320/25mg once daily Dosing is individualised and according to product insert / protocol. | |
| 1650 | Valsartan 80 mg Tablet | C09CA03-000-T10-01-XXX | A/KK | Patients intolerant to ACE inhibitors in: i) Heart failure ii) Post myocardial infarction iii) Hypertension | i) Initial: 40mg twice daily. Titrate up to highest tolerated dose. Max: 320mg daily in divided doses ii) Initial: 20mg twice daily Titrate up to 160mg over next few weeks. Max: 160mg twice daily iii) 80mg or 160mg once daily Max: 320mg daily Dosing is individualised and according to package insert / protocol. |